Price T Rowe Associates Inc Eagle Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 13,300 shares of EGRX stock, worth $11,970. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,300

Previous 13,300 -0.0%

Holding current value

$11,970

Previous $75,000 33.33%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.34 - $5.6 $8,176 - $13,708	-2,448 Reduced 15.54%	13,300 $75,000
Q1 2024 May 15, 2024	BUY	$4.26 - $6.51 $67,086 - $102,519	15,748 New	15,748 $83,000
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $25,429 - $40,485	1,018 Added 6.84%	15,893 $465,000
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $138,203 - $246,484	5,231 Added 54.24%	14,875 $393,000
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $142,099 - $176,849	-3,444 Reduced 26.31%	9,644 $428,000
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $7,979 - $9,415	-179 Reduced 1.35%	13,088 $648,000
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $9,530 - $11,835	-208 Reduced 1.54%	13,267 $676,000
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $437 - $557	-10 Reduced 0.07%	13,475 $752,000
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $57,280 - $69,153	-1,554 Reduced 10.33%	13,485 $577,000
Q1 2021 May 17, 2021	SELL	$40.32 - $50.97 $193,576 - $244,706	-4,801 Reduced 24.2%	15,039 $628,000
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $827,724 - $1.02 Million	19,840 New	19,840 $924,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.35M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $11.7M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Eagle Pharmaceuticals, Inc. Transaction History